GSK Pharma stock enters a results blackout before Q2 FY27

Published on 10/01/2026 at 06:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q1 FY27 revenue reached INR 9.38 billion, up 16.52 percent from a year earlier. GSK Pharma's trading window closed on October 1 before the September 2026 quarter and half year results.

GSK Pharma, INE159A01016, Illustration mit AI erstellt.

GSK Pharma (ISIN INE159A01016) had a market capitalization of INR 469.1 billion as of September 30, 2026, while its trading window closed on October 1 ahead of the next results cycle. The company is preparing to report figures for the quarter and half year ended September 30, 2026.

Results blackout sets the next checkpoint

According to ScanX News on September 25, 2026, GlaxoSmithKline Pharmaceuticals Limited closed its trading window from October 1, 2026, until 48 hours after the announcement of its unaudited Q2 and half year FY27 results.

The filing timetable gives the September 2026 quarter a defined comparison point. The company will report against Q2 FY26, which covered the September 2025 quarter, while the latest published interim figures come from Q1 FY27.

Q1 growth raises the comparison bar

Univest reported that Q1 FY27 revenue reached INR 9.38 billion, up 16.52 percent from INR 8.05 billion in Q1 FY26. Net profit rose 15.61 percent to INR 2.37 billion from INR 2.05 billion over the same comparison.

The sequential picture was more restrained. Revenue declined from INR 9.95 billion in Q4 FY26 to INR 9.38 billion in Q1 FY27, while net profit decreased from INR 2.78 billion to INR 2.37 billion. That contrast makes the September quarter's year over year comparison especially important for the stock.

GSK India's investor page identifies Q1 FY2027 as the latest financial-results release and describes the business as a focused biopharma company covering medicines and vaccines across respiratory, immunology and inflammation, oncology, HIV and infectious diseases.

Stock range frames the valuation

GSK Pharma's 52-week range was INR 2,088.10 to INR 3,120.70 as of September 30, 2026. The stock was listed on the National Stock Exchange under GLAXO and on the Bombay Stock Exchange under 500660, with the market value at INR 469.1 billion on the same date.

For investors, the key numerical test is whether Q2 FY27 can build on the 16.52 percent revenue growth and 15.61 percent profit growth delivered in Q1 FY27 while recovering from the sequential decline. The results announcement will also show how margins compare with the 31.0 percent operating margin reported for Q1 FY27.

GSK Pharma stock awaits the next report

GSK Pharma stock enters the September-quarter reporting phase with Q1 FY27 revenue of INR 9.38 billion, Q1 FY27 net profit of INR 2.37 billion and a market capitalization of INR 469.1 billion as of September 30, 2026. The next disclosed figures will cover Q2 and half year FY27, ending September 30, 2026.